10-1074-LS
- Generic Name
- 10-1074-LS
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 135
- Registration Number
- NCT06205602
- Locations
- π§πΌ
Gaborone CRS (12701), Gaborone, Botswana
πΏπ¦University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg, Gauteng, South Africa
πΏπ¦CAPRISA eThekwini CRS (31422), Durban, KwaZulu-Natal, South Africa
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 45
- Registration Number
- NCT06071767
- Locations
- π§π·
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre, Rio Grande Do Sul, Brazil
πΊπΈUniversity of California, San Diego AntiViral Research Center CRS, San Diego, California, United States
πΊπΈPonce de Leon Center CRS, Atlanta, Georgia, United States
A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05729568
- Locations
- πΊπΈ
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
πΊπΈCan Community Health Care, Fort Lauderdale, Florida, United States
πΊπΈEmory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 200
- Registration Number
- NCT05612178
- Locations
- πΊπΈ
The Rockefeller University, New York, New York, United States
πΊπΈNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 28
- Registration Number
- NCT05245292
- Locations
- πΊπΈ
Weill Cornell Medicine, Cornell Clinical Trials Unit, New York, New York, United States
πΊπΈThe Rockefeller University, New York, New York, United States
πΊπΈPerelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, United States
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
- Locations
- πΊπΈ
Alabama CRS, Birmingham, Alabama, United States
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT04811040
- Locations
- πΊπΈ
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈThe Brody School of Medicine at East Carolina University, ECU Adult Specialty Care, Greenville, North Carolina, United States
πΊπΈBe Well Medical Center, Berkley, Michigan, United States
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 118
- Registration Number
- NCT04340596
- Locations
- πΊπΈ
New Jersey Medical School Clinical Research Center CRS [Site ID: 31786], Newark, New Jersey, United States
πΊπΈColumbia P&S CRS, New York, New York, United States
πΊπΈWeill Cornell Uptown CRS (Site ID: 7803), New York, New York, United States
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 6
- Registration Number
- NCT04250636
- Locations
- πΊπΈ
Weill Cornell Medical Center Clinical Trials Unit-CLOSED SITE, New York, New York, United States
πΊπΈPerelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈThe Rockefeller University, New York, New York, United States
Dual bNAb Treatment in Children
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 30
- Registration Number
- NCT03707977
- Locations
- π§πΌ
Francistown Non-Network CRS, Francistown, Botswana
π§πΌBotswana Harvard AIDS Institute Partnership CRS Non-Network, Gaborone, Botswana
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.